By Devika Patel
Knoxville, Tenn., Oct. 1 - Oxigene Inc. completed a $2.48 million private placement of shares on Wednesday, according to an 8-K filed Wednesday with the Securities and Exchange Commission.
The company sold 2,231,636 common shares at $1.11 per share to Symphony ViDA Holdings LLC.
Symphony also received warrants exercisable for 11,281,877 shares at $1.11 for ten years.
Proceeds will support pre-clinical and clinical development of Oxigene's product candidates, Zybrestat and OXi4503.
Oxigene is a pharmaceutical company located in Waltham, Mass.
| Issuer: | Oxigene Inc.
|
| Issue: | Common stock
|
| Amount: | $2,477,115.96
|
| Shares: | 2,231,636
|
| Price: | $1.11
|
| Warrants: | For 11,281,877 shares
|
| Warrant expiration: | Ten years
|
| Warrant strike price: | $1.11
|
| Investor: | Symphony ViDA Holdings LLC
|
| Settlement date: | Oct. 1
|
| Stock symbol: | Nasdaq: OXGN
|
| Stock price: | $1.29 at close Oct. 1
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
